 Primary objective is to estimate the overall response rate ORR and the complete response rate CRR to the VcR CVAD regimen response rate at completion of induction. Patients will receive Rituximab, Bortezomib, cyclophosphamide, Doxorubicin, Vincristine, Dexamethasone in three week intervals for 6 cycles; then rituximab consolidation weekly x 4 , then one dose of rituximab every 12 weeks until 5 years or disease progression. 